Pharmacological treatments use medicines to help manage certain forms of non-melanoma skin cancer (NMSC) and related precancerous skin conditions. These therapies are typically applied directly to the skin and may be considered for selected superficial lesions, areas with multiple lesions, or patients for whom other treatment approaches may not be suitable.
The choice of treatment depends on several factors, including the type of skin cancer, its size and location, the patient’s overall health, and the goals of treatment. A healthcare professional can help determine which treatment options may be appropriate for an individual’s circumstances. The following treatment options are most commonly used to treat early-stage non-melanoma skin cancer (NMSC), although they may also be used in other situations.
Topical Pharmacological Treatments
Topical treatments are medicines applied directly to the skin. They work by targeting abnormal cells within the treatment area and are generally prescribed and monitored by a healthcare professional.
Imiquimod
Imiquimod is an immune response modifier that stimulates the body’s natural immune system to recognise and respond to abnormal skin cells.
It is commonly used in the management of certain superficial skin lesions and may be prescribed over a period of several weeks, depending on the treatment plan. Local skin reactions such as redness, irritation, crusting, or inflammation are common during treatment.
Key Characteristics
- Applied directly to the skin
- Works by activating the body’s immune response
- Typically used over multiple weeks
- Requires monitoring by a healthcare professional
- Temporary skin reactions are common during treatment
5-Fluorouracil (5-FU)
5-Fluorouracil is a topical chemotherapy medication that interferes with the growth and replication of abnormal skin cells.
It has been used for many years in dermatology and may be prescribed for certain superficial skin lesions or precancerous skin changes. Treatment duration varies depending on the condition being treated and the healthcare professional’s recommendations.
During treatment, the skin may become red, inflamed, tender, or crusted before healing occurs.
Key Characteristics
- Topical chemotherapy agent
- Targets rapidly growing abnormal cells
- Applied over a prescribed treatment period
- Local skin reactions are expected during treatment
- Requires follow-up assessment by a healthcare professional
Diclofenac Gel
Diclofenac is a non-steroidal anti-inflammatory medication available as a topical gel formulation.
It is primarily used in the management of precancerous skin lesions such as actinic keratosis and may be prescribed as part of a broader skin management plan. Treatment is generally administered over an extended period and requires monitoring by a healthcare professional.
Key Characteristics
- Anti-inflammatory topical medication
- Applied directly to affected skin areas
- Typically used for extended treatment courses
- Generally well tolerated
- Requires ongoing clinical review
What to Expect During Treatment
Pharmacological treatments often require patients to apply medication at home according to a prescribed schedule. The treatment area may undergo visible changes during therapy, including redness, scaling, crusting, or inflammation.
These reactions can vary between individuals and between treatment types. Patients should follow their healthcare professional’s instructions carefully and attend any recommended follow-up appointments to assess treatment response and skin healing.
Potential Treatment Considerations
Pharmacological therapies provide an additional treatment option for selected patients and clinical situations. However, not every treatment is suitable for every lesion or every patient.
Factors that may influence treatment selection include:
- Type and characteristics of the lesion
- Location on the body
- Size and number of lesions
- Patient preferences and lifestyle considerations
- Previous treatments
- Overall health and medical history
A healthcare professional can discuss the potential benefits, limitations, and expected outcomes of each treatment option.
Discussing Your Options
If you have been diagnosed with non-melanoma skin cancer or a related skin condition, it is important to discuss all available treatment options with your healthcare team.
Treatment decisions should be based on individual clinical circumstances, taking into account the characteristics of the lesion, treatment objectives, and personal preferences. Your healthcare professional can help determine which management approach may be most appropriate for your situation.
This information is intended for educational purposes only and should not replace professional medical advice. Please note that treatment availability, approved indications and clinical practice may vary between countries and may change over time. Patients should seek advice from their treating healthcare professional regarding their individual circumstances. Treatment decisions should always be made in consultation with a qualified healthcare professional.
Sources:
- Cancer Council Australia – Clinical Practice Guidelines for Keratinocyte Cancers
- National Comprehensive Cancer Network (NCCN) Guidelines for Basal Cell Skin Cancer and Squamous Cell Skin Cancer
- European Consensus-Based Interdisciplinary Guideline for Diagnosis and Treatment of Basal Cell Carcinoma (Update 2023)
- European interdisciplinary guidelines for invasive cutaneous squamous cell carcinoma
- American Academy of Dermatology (AAD) clinical resources
- Regulatory information published by the European Medicines Agency (EMA)